Stay updated on GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.

Latest updates to the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check12 days agoChange DetectedGenSight Biologics is added as sponsor and Magali Taiel, MD is removed as investigator.SummaryDifference0.4%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe screenshots show only visual/layout adjustments and an updated timestamp; no substantive changes to the study details.SummaryDifference0.1%

- Check33 days agoChange DetectedThe page revision updated from v3.4.1 to v3.4.2. There are no evident changes to the core study details or content.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1. No other content on the page appears to have changed.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded a glossary toggle and updated QC metadata to show 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with 'Revision: v3.4.0'; the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

Stay in the know with updates to GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.